Neurology News

CHICAGO — Suicide is the 10th leading cause of death in the United States, and it is more common among physicians than among the general population, according to speakers at the ACP Internal Medicine Meeting.

The FDA approved an expanded indication for a transcarotid stent system to include patients at standard risk for adverse events from carotid endarterectomy, according to a press release from Silk Road Medical.

The FDA has issued a complete response letter to Axsome Therapeutics Inc., in which the agency declined to move forward with a new drug application for AXS-07, an acute treatment for migraine.

A computerized diagnostic tool was able to distinguish patients with normal cognition, mild cognitive impairment and dementia and may be useful in detecting early signs of cognitive impairment, according to a study published in JMIR Aging.

One of the most important components of a sound financial strategy is to mitigate risk.

CHICAGO — The ACP recently released a position paper that lays out recommendations for improving communication between primary care and specialty physicians, which in turn will improve patient care.

Pfizer revealed plans to open sites in the U.S. for a phase 3 study evaluating an investigational mini-dystrophin gene therapy in ambulatory patients with Duchenne muscular dystrophy.

With the launch of his direct-to-consumer online pharmacy, billionaire entrepreneur Mark Cuban aims to provide prescription drugs at lower prices than other online retailers and those mediated by pharmacy benefit managers.

AstraZeneca has announced FDA approval of Ultomiris, a long-acting C5 complement inhibitor for the treatment of adults with generalized myasthenia gravis.

The FDA and European Commission have both granted orphan drug designation to AviadoBio for its new gene therapy to treat frontotemporal dementia, according to a company press release.